Rare genetic disorders
We support innovative biotechs in Italy as they push promising research programs in rare genetic disorders towards preclinical and clinical development.
Our unique collaboration with the Telethon Foundation aims to bring Italian scientific excellence to the world stage. Our mission is to foster a thriving biotech ecosystem in Italy.
| Close | Fund | AMT |
|---|---|---|
| 2018 | Sofinnova Telethon Fund | €108 million |
Close: 2018
Fund: Sofinnova Telethon Fund
AMT: €108 million
The Sofinnova Telethon Fund is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.
“We come from the tech transfer world so we understand what it takes to build companies around the expertise at universities and institutions."
“There has to be more willingness to invest in the early stage. If nobody had invested in mRNA technology 10 years ago, I don't think we would have had the Covid vaccine in less than one year.”
"I am passionate about science and committed to helping great ideas find their way to patients, so working at Sofinnova Partners is a perfect fit."
Companies
Fund iteration
Status
Deal lead
Related News
AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa
AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
AAVantgarde announces first patient dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 study for retinitis pigmentosa related to USH1B